AGN has been the topic of a number of other research reports. J P Morgan Chase & Co set a $275.00 price objective on shares of Allergan PLC. and gave the stock a buy rating in a research note on Sunday, October 22nd. BidaskClub lowered shares of Allergan PLC. from a sell rating to a strong sell rating in a research note on Friday, August 25th. Mizuho restated a buy rating and set a $267.00 price target on shares of Allergan PLC. in a research report on Monday, September 25th. Wells Fargo & Company restated an outperform rating and set a $258.00 price target on shares of Allergan PLC. in a research report on Wednesday, October 18th. Finally, Citigroup Inc restated a buy rating and set a $280.00 price target on shares of Allergan PLC. in a research report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating to the company. Allergan PLC. currently has an average rating of Hold and a consensus price target of $246.73.
Shares of Allergan PLC. (NYSE AGN) traded down $9.66 during trading on Thursday, reaching $174.92. 3,283,512 shares of the company’s stock were exchanged, compared to its average volume of 4,520,000. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.13 and a quick ratio of 1.10. Allergan PLC. has a twelve month low of $169.64 and a twelve month high of $256.80. The firm has a market cap of $58.33 billion, a price-to-earnings ratio of 11.37, a price-to-earnings-growth ratio of 0.93 and a beta of 1.12.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 7.86%. Allergan PLC.’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.32 EPS. equities research analysts anticipate that Allergan PLC. will post 16.28 EPS for the current fiscal year.
Allergan PLC. declared that its Board of Directors has initiated a share repurchase program on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently -12.39%.
Institutional investors have recently modified their holdings of the stock. Honeywell International Inc. lifted its stake in Allergan PLC. by 13.6% in the second quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after acquiring an additional 20,100 shares during the last quarter. Israel Discount Bank of New York purchased a new position in Allergan PLC. in the first quarter worth approximately $988,000. Sumitomo Life Insurance Co. lifted its position in shares of Allergan PLC. by 39.0% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 15,122 shares of the company’s stock worth $3,099,000 after buying an additional 4,244 shares during the last quarter. Colony Group LLC lifted its position in shares of Allergan PLC. by 9.9% during the 2nd quarter. Colony Group LLC now owns 39,802 shares of the company’s stock worth $9,675,000 after buying an additional 3,577 shares during the last quarter. Finally, Palladium Partners LLC lifted its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after buying an additional 523 shares during the last quarter. Institutional investors own 82.02% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.